{"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}],"groups":[{"description":"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1-2 hours on day -6.\n\nARM 1(patients at low risk for graft failure) - patients receive 200cGy TBI ARM 2 (patients at high risk for graft failure) - patients receive 300cGy TBI\n\nUMBILICAL CORD BLOOD TRANSPLANT: Patients undergo donor umbilical cord blood infusion on day 0.\n\nIMMUNOSUPRESSIVE THERAPIES: Patients receive cyclosporine IV over 1 hour every 8-12 hours on days 0 to +180 and mycophenolate mofetil IV or PO every 8 hours on days -3 to +96.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo single or double umbilical cord blood transplant","id":"BG000","title":"Treatment (Chemotherapy, Transplant)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"13","upperLimit":"73","value":"60"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}]}],"description":"Patients \\> 70 may be considered if performance status \\> 80% or Eastern Cooperative Oncology Group (ECOG) =\\< 1 and comorbidity score \\< 3; these patients must be discussed with the principal investigator (PI), Rachel Salit prior to enrollment","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"42"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"54"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}],"title":"100"},{"measurements":[{"groupId":"BG000","value":"29"}],"title":"90"},{"measurements":[{"groupId":"BG000","value":"18"}],"title":"80"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"70"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"50"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"unknown"}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}]}],"description":"Scale from 0-100 with\n\n100= Normal no complaints 90= Normal activity with minor signs or symptoms of disease 80= Normal activity with effort, some signs or symptoms of disease 70= Cares for self, unable to carry on normal activity 60= Requires occasional assistance 50= Requires considerable assistance 40= Disabled 30= Severely disabled 20= Very sick, hospitalized 10= Moribund 0= Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"Karnofsky Performance Scale","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"2"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"3"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":"4"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"5"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"6"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"7"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"8"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"unknown"}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}]}],"description":"The HCT-CI is a comorbidity index that comprises 17 different categories of organ dysfunction. Positive findings are summated into a total score. The HCT-CI provides information with regard to the overall as well as non-relapse mortality risk a patient is likely to experience after hematopoietic cell transplantation. Lower scores have been shown to be associated with lower non relapse mortality.","paramType":"COUNT_OF_PARTICIPANTS","title":"Hematopoeitic Cell Transplant Comorbidity Index","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45"}],"title":"CMV Seropositive"},{"measurements":[{"groupId":"BG000","value":"26"}],"title":"CMV Seronegative"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"unknown"}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Cytomegalovirus Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"38"}],"title":"AML"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"ALL"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"MDS"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Hodgkins"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Non Hodgkins Lymphoma"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Peripheral T cell Lymphoma"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Disease","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56"}],"title":"Complete Remission"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Partial Remission"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Stable Disease"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Remission Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"}],"title":"MRD positive"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"MRD negative"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"unknown"}],"denoms":[{"counts":[{"groupId":"BG000","value":"56"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only patients in a complete remission were assessed for minimal residual disease. All others are known to have residual disease","title":"Minimal Residual Disease","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Single Cord"},{"measurements":[{"groupId":"BG000","value":"70"}],"title":"Double Cord"}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Number of cord blood donors","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}],"title":"4/6 plus 4/6"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"4/6 plus 5/6"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"5/6 plus 5/6"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"6/6 plus 6/6"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"other"}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}]}],"description":"The standard for selecting unrelated umbilical cord blood units for transplantation for non-malignant diseases relies on antigen-level (lower resolution) HLA typing for HLA-A and HLA-B, and allele-level for HLA-DRB1. A 6 of 6 cord blood in matched at A, B and DR on both Haplotypes. 5 of 6 has one mismatch and 4 of 6 has 2 mismatched. 4 of 6 is commonly the maximum number of mismatches accepted for a cord blood transplant.","paramType":"COUNT_OF_PARTICIPANTS","title":"Level of HLA matching","unitOfMeasure":"Participants"}]}